Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy.
about
Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infectionsPleiotropic role of the RNA chaperone protein Hfq in the human pathogen Clostridium difficileSynthetic polymers active against Clostridium difficile vegetative cell growth and spore outgrowthLong-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center StudyGenome-wide identification of regulatory RNAs in the human pathogen Clostridium difficile.Investigation and management of Clostridium difficile colonisation in a paediatric oncology unit.Treatment of Clostridium difficile-associated diarrhea.Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy.Function of the CRISPR-Cas System of the Human Pathogen Clostridium difficile.Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin ProductionPathogenesis and treatment of Clostridium difficile infectionRelapse versus reinfection with Clostridium difficile.Stool therapy may become a preferred treatment of recurrent Clostridium difficile?Management and prevention of recurrent clostridium difficile infection in patients after total joint arthroplasty: a review.Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro modelgyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.Diarrheal disease in the hospitalized patient.Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters.Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease.The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in Clostridium difficile.Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production.Recurrent Clostridium difficile colitis. Tackling a tenacious nosocomial infection.Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment.
P2860
Q24529831-6DB38C99-8B8F-4671-AFD6-23A202435C30Q26752760-1B127E01-1D31-4AE2-8655-45126FE9CC0BQ34056874-62382969-E706-47AB-8453-26F2F83E726BQ34408053-A6819419-C2D7-45D1-A4B4-FE7D90F3229CQ34429629-BB56E63A-59FB-4919-B54D-9BD2AE4D3692Q34722556-8C6B8CEA-3FC2-44DD-B070-E3B67FD522D6Q34795894-1328AB2F-0B66-4EDF-BD52-6630BA7EFB40Q34979678-DE33ADA2-5474-461F-A07A-A351925658F2Q35596453-A2D64F05-7A94-4509-9D42-430AC40AEF65Q36017330-72B61578-2432-4843-AE47-17EA8AABBD1FQ36111393-DC2C46A1-2F01-4B9E-A3D8-9D905BB06394Q36152528-12DAE827-1898-4DFF-A033-F5036DDE1B66Q36505810-5C6CDCC0-6208-4241-8082-3769B52481C9Q37068231-E9E93530-C991-46A3-B843-1663366DB6B0Q38097440-94D102FB-D434-42CB-83F3-69081FDC1559Q39478033-D8F68BB7-FC32-483D-B775-F378CD6DE617Q39554726-D19BED25-628F-4556-AEC1-A472C5E041A3Q39564798-1706E4D2-FADC-4749-8969-E12285AD2172Q39657922-78B50BAB-23CA-470E-9419-BC64B2A24CBDQ39751834-920213D5-F491-4DA0-8FB4-78A26EECB4E9Q39827540-D01ED96D-9F26-483F-9698-26C862F168FDQ40840258-A04ED316-E75E-4743-8FA5-76245603F45AQ41878757-3565D086-D6AC-47D4-8BDB-E94C05B3E6A9Q42688761-0C6B0513-D6EF-4980-980A-23CBBEC04B83Q43727421-2ED75F70-ECC2-479E-BBDF-F38158787ABBQ44897788-FEBD2CE2-B893-47B7-A9F2-1B0E30C8370FQ50608427-6989B06D-F8F2-4460-B616-1FA3C15DDF66
P2860
Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy.
description
1983 nî lūn-bûn
@nan
1983 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1983 թվականի մարտին հրատարակված գիտական հոդված
@hy
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
name
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@ast
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@en
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@nl
type
label
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@ast
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@en
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@nl
prefLabel
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@ast
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@en
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@nl
P2093
P2860
P356
P1433
P1476
Relapse of antibiotic associat ...... ile during vancomycin therapy.
@en
P2093
Seneviratne E
Stafford R
Walters BA
P2860
P304
P356
10.1136/GUT.24.3.206
P407
P577
1983-03-01T00:00:00Z